JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The Prognostic Value of Serum Sialic Acid in Patients with Nasopharyngeal Carcinoma: A Propensity Score Matching Study

  • 0Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530021, People's Republic of China.
Cancer Management and Research +

|

March 25, 2024

|

March 25, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

High serum sialic acid (SA) levels indicate a poor prognosis in nasopharyngeal carcinoma (NPC) patients. Elevated SA is an independent adverse prognostic factor for survival in NPC without distant metastasis.

Area Of Science

  • Oncology
  • Biochemistry

Background

  • Elevated serum sialic acid (SA) is a known indicator of poor prognosis in various cancers.
  • Nasopharyngeal carcinoma (NPC) is a significant malignancy with variable survival outcomes.

Purpose Of The Study

  • To investigate the association between serum SA levels and survival prognosis in NPC patients.
  • To determine if serum SA is an independent prognostic factor in NPC.

Main Methods

  • Retrospective analysis of 293 NPC patients treated with intensity-modulated radiotherapy (IMRT) from 2014-2016.
  • Serum SA levels were measured pre-treatment, with an optimal cut-off determined by X-tile software.
  • Propensity score matching (PSM) was used to balance baseline characteristics, followed by survival analysis using Kaplan-Meier and Cox regression models.

Main Results

  • An optimal cut-off for serum SA was determined to be 65.10 mg/dl.
  • Higher serum SA levels were significantly associated with poorer locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS).
  • Multivariate analysis identified high serum SA expression as an independent adverse prognostic factor for PFS and OS in NPC patients without distant metastasis.

Conclusions

  • Pre-treatment serum SA levels > 65.10 mg/dl are linked to adverse survival outcomes in NPC.
  • Serum SA is an independent prognostic factor for NPC patients with no distant metastasis, highlighting its clinical relevance.

Keywords: